Antibodies with reduced net positive charge
AssigneeTechniclone, Inc.
InventorsLeslie A. Khawli, Alan L. Epstein
Life of this patent
Estimating the term…
Abstract
Modified antibodies which have been by chemical conjugation with agents reactive with free amino groups are disclosed. Among the chemical agents disclosed for use in connection with the invention are heterobifunctional reagents and biotin. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
Claims11
A composition of matter, comprising:
- an antibody conjugated to biotin at at least one of a plurality of free amino groups disposed on the antibody to produce a modified antibody, said antibody having a reduced net positive charge compared to intact antibody, said antibody having an in vivo clearance rate between the clearance rates of F(ab').sub.2 fragments and intact antibodies of the same type with the proviso that said biotin is not bound to said antibody through a heterobifunctional agent;
- and
- a chemical moiety attached to the modified antibody.
A composition of matter, comprising:
- an antibody conjugated to a chemical reagent at at least one of a plurality of free amino groups disposed on the antibody to produce a modified antibody, said antibody having a reduced net positive charge compared to intact antibody, said antibody having an in vivo clearance rate between the clearance rates of the F(ab').sub.2 fragments and intact antibodies of the same type, with the proviso that said chemical reagent is not a heterobifunctional agent;
- and
- a chemical moiety attached to the modified antibody, wherein said chemical moiety comprises ricin A-chain.
Dependencies are inferred from the claim text.